Fuse Biotherapeutics is a Los Angeles, CA–based biotechnology company developing immune‑modulating therapeutics that direct and potentiate both innate and adaptive immunity. Its therapeutic approach integrates multiple steps of an immune response so that potent responses to danger are targeted without natural breaks that spare healthy tissue. The company is developing a proprietary platform that leverages the inherent capacity of NK cells to distinguish between normal and diseased tissues. Led by Co‑Founder and CEO Paul Y. Song, MD, Fuse focuses on immune‑modulating approaches for patients with cancer. The company intends to use the seed proceeds to further develop that proprietary NK‑cell‑focused platform. No operating metrics were disclosed in the article.

Total raised

$10M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2021